Impact of prognostic factors and risk groups onoverall survival in patients treated with pembrolizumab vs investigator's choice chemotherapy for advanced urothelial cancer: post HOC Analysis of Keynote-045

Category Primary study
ConferenceAsia-Pacific Journal of Clinical Oncology
Year 2019
This article has no abstract
Epistemonikos ID: d0272bb536ac5c4311ad5b77fcf6fc2459c9a5c9
First added on: Apr 30, 2026